Skip to main content

Share story

AI Science

Preprint tests shared reasoning to counter corrupted AI majorities

Researchers report that letting AI agents take turns extending a shared, unfinished reasoning process improves answer accuracy when a majority receives instructions favoring an incorrect answer. Their preprint introduces a method that combines several such shared trajectories through a final vote. The approach lets a minority insert corrections before answers are complete, allowing subsequent agents to read them. Across model families and verifiable reasoning benchmarks, the researchers report substantial gains under majority corruption and comparable average performance under minority corruption. Parallel local serving added modest measured latency. The findings concern an experimental setting in which agents receive advisory instructions favoring wrong answers.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from cs.CL updates on arXiv.org and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.